Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Explore when to make changes to your spending plan and how to rebalance categories so you stay aligned with goals and cash flow.
23,566 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
UPS sinks about 11% after weaker quarterly results, while FedEx surges past UPS in market value following a stronger ...
Tilray Brands is expanding beyond its cannabis roots into beverages and other segments. This article examines whether...
Investor nerves rose as here's gemini space station faced a sharp price drop this week. This piece breaks down what s...
Guardian (GRDN) is shaping up as a data-driven growth story in 2026. This deep dive breaks down the Q1 2026 earnings ...
SVB Capital, the bank's roughly $10 billion venture arm, is being shopped as regulators unwind SVB assets. Buyers are...
Nvidia stock has hit a new all-time high as AI demand accelerates. This article breaks down the drivers behind the ra...
A sharp rise in Alumis shares coincides with a fresh stake from Cormorant Asset Management. This article breaks down ...
A decade-long track record of dividend growth has helped Vanguard Dividend Appreciation ETF outpace many high-yield r...
MicroStrategy is pursuing a sizable buyback of zero-coupon convertible notes, a move some critics say reveals liquidi...
CoreWeave's backlog booming has caught the eye of investors eyeing AI infrastructure. This piece breaks down whether ...
If you’re weighing fncl kbwb: broad financial exposure against a concentrated bank bet, this guide breaks down how ea...